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GVHD were marginally lower after HLA matched or mismatched
UCB transplants than after allele-matched BM. Notably, leuke-
mia-free survival (LFS) rates at 5 years were comparable between
those receiving allele matched BM (38%) and 1 locus high cell dose
(41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mis-
matched UCB. The observed higher LFS rate (60%) after HLA
matched UCB transplant requires validation in a larger cohort.
These results in LFS are in part explained by differences in risks of
transplant related mortality (TRM) and relapse between patient
populations. Compared to allele-matched BM transplants, TRM
was similar in recipients of matched and 1-locus mismatched UCB
and higher in recipients of 2-loci mismatched UCB. Conversely,
relapse rates were lower in recipients of UCB transplants mis-
matched at 2-HLA loci. These results are the ﬁrst to support the
use of HLA matched or mismatched UCB grafts with an adequate
cell dose as a ﬁrst line transplant treatment regardless of the
availability of a HLA allele-matched BM donor in the setting of
acute leukemia in children aged 16 years.
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Graft nucleated cell and CD34 hematopoietic progenitor cell
dose are predictors of allogeneic engraftment and survival in um-
bilical cord blood (UCB) recipients. In this single institution pro-
spective phase II trial, ﬂow cytometric analyses of CD34 progen-
itor and lymphocyte populations in unmodiﬁed single unit HLA-
disparate UCB grafts infused into 31 consecutive adults (median
age 41 years, range 20-64) receiving myeloablative conditioning
were compared with clinical outcomes. Median infused UCB graft
nucleated cells and CD34 dose was 2.2  107/kg and 1.2 
105/kg respectively. Day to absolute neutrophil count  500/L
with full donor chimerism averaged 27 days (range 12-41). Uni-
variate analyses demonstrated that UCB graft infused cell doses of
CD34 (p0.015), CD3 (p0.024) and CD34HLADR
CD38 progenitors (p0.043) correlated with neutrophil engraft-
ment. High-resolution matching for HLA-Class II (DRB1) re-
sulted in improved event-free survival (EFS) (p0.02) and de-
creased risk for acute graft versus host disease (GVHD) (p0.004).
Early mortality (prior to post-transplant day 28) occurred in
three patients, while twenty-six patients achieved myeloid engraft-
ment. These results suggest that UCB graft matching at DRB1 is
an important risk factor for acute GVHD and survival, while
higher UCB graft cell doses of CD34, committed CD34 pro-
genitors and CD3 T-cells favorably inﬂuence UCB allogeneic
engraftment.
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Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable
donors, reducing the risks of acute and chronic graft-versus-host
disease (GVHD) and improving survival. Cell dose, however, has
clearly been identiﬁed as a major limitation, often preventing the
consideration of UCB for adult recipients. Recipients of 2.5 
107 nucleated cells/kg have slow hematopoietic recovery and sig-
niﬁcantly lower incidence of engraftment. Therefore, we explored
the potential of infusing two partially HLA matched units to
augment cell dose in patients who did not have an UCB graft
containing2.5 107 nucleated cells/kg. The underlying hypoth-
esis is that the addition of the second unit will enhance engraftment
and speed of hematopoietic recovery. One-hundred and twenty-
two patients [median age 23.2 years (range: 2.9-45.8); median
weight 64 kg (range: 12.6-148.6)] with high-risk hematologic ma-
lignancy were transplanted with a partially HLA-matched UCB
graft (70% received two units) after a single myeloablative condi-
tioning consisting of ﬂudarabine 75 mg/m2, cyclophosphamide 60
mg/kg and total body irradiation 1320 cGy. All received cyclospor-
ine and mycophenolate mofetil posttransplant immunoprophylaxis.
Patients had AML (n51), ALL (n46), CML (n10), MDS
(n4) or NHL (n11). The median total infused dose was 4.4 
107 NC/kg (range 1.1-13.9). The incidence of neutrophil recovery
was 91% (95% CI, 86-96) at a median of 23 days with no difference
observed in recipients of one or two units. Only CD34 cell dose
predicted incidence and speed of recovery. After engraftment, one
unit predominated in 90% with no factor (nucleated cell dose,
CD34 cell dose, HLA-match, ABO, sex, or order of infusion)
predicting which unit would predominate long term. Incidence of
grades II-IV and III-IV acute graft-versus-host disease (GVHD)
was 55% (95% CI, 44-66) and 17% (95% CI, 9-25) at day 100 with
an increased incidence of grade II disease only in recipients of two
units. Incidences of transplant-related mortality and relapse was
25% (95% CI, 17-33) at 1 year and 22% (95% CI, 12-32) at 2
years, respectively. Probabilities of overall and event-free survival
are 59% (95% CI, 49-69) and 51% (95% CI, 40-62) at 2 years,
respectively. Notably, recipients of two units had a trend toward
reduced relapse and improved event-free survival. These data sug-
gest that 1) double unit UCBT is safe with one unit predominating
over time, 2) double unit UCBT may extend the application of
UCB to nearly all adults and adolescents, and 3) double UCBT
may be associated with lower relapse and higher survival in those
with acute leukemia in complete remission. A NIH-CTN spon-
sored, multi-institutional randomized trial comparing outcomes in
recipients of single versus double UCB transplantation is open for
accrual.
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A major goal of our laboratory and the focus of this presentation
is to enhance the efﬁciency of cord blood transplantation through
a better understanding of the mechanisms regulating hematopoi-
esis, and hematopoietic stem (HSC) and progenitor cell functions.
We have found that inhibition of CD26/Dipeptidylpeptidase IV
(DPPIV) with small peptides, such as Diprotin A (Ile-Pro-Ile) or
Val-Pyr enhance the capacity of human cord blood CD34 cells
and mouse Sca1c-kitLin bone marrow cells to respond to the
chemotactic activity of stromal cell derived factor (SDF-1/
CXCL12) in vitro (Christopherson, et al. J. Immunol 169:7000-
7008, 2002) and they enhance donor mouse bone marrow HSC
homing and engraftment of lethally irradiated recipient mice in
both a competitive and a non-competitive assay (Christopherson,
et al. Science 30:1000-1003, 2004). Enhanced engrafting capability
of gene transduced mouse bone marrow cells into lethally irradi-
ated mice (Tian, et al. Gene Therapy 13:652-658, 2006) and mouse
bone marrow cells in utero into mice (Peranteau, et al. Blood
108:4268-4274, 2006) has been noted by others in the context of
Diprotin A inhibition of CD26/DPPIV on donor cells. We now
report that inhibition of CD26/DPPIV in human cord blood
CD34 cells enhances their engraftment of non obese diabetic
(NOD)/Severe Combined Immunodeﬁcient (SCID) mice (Camp-
bell, et al. Stem Cells and Development [SCD], 16:347-353, 2007).
Others have seen Diprotin A enhancement of CD34 cord blood
(Christopherson, et al. SCD 16:355-360, 2007) and G-CSF mobi-
lized adult peripheral blood CD34 (Kawai, et al. SCD 16:361-
370, 2007) cells respectively by pretreating donor CD34 cells, or
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